Next quarterly is in 6 weeks time. I can only assume that the trajectory of sales/revenue/margins are all heading in the right direction.
More people aware of sleep apnoea means more treatment.
There are few companies on the ASX that can boast growth rates like that ^^ Buying the ~$22.50 dip last year allowed me to get in at pre-covid prices.
There is no reason that I can see that GLP-1 and other weight loss drugs are going to severely affect RMD earnings.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$38.52 |
Change
-0.330(0.85%) |
Mkt cap ! $22.41B | |||
| Open | High | Low | Value | Volume |
| $38.67 | $38.67 | $38.15 | $26.37M | 686.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 361 | $38.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.55 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| RMD (ASX) Chart |